Vitreq has been sold to Beaver-Visitec International

The shareholders of Vitreq have sold the company to Beaver-Visitec International, a portfolio company of TPG Capital.

Vitreq, founded in 2014 by a team of industry professionals with a proven track record, is a next-generation ophthalmic technology company. Headquartered in the Netherlands, Vitreq creates instruments for the ophthalmic society with a special focus on vitreoretinal surgery. At Vitreq, a dedicated team of R&D, engineering, QA-RA and manufacturing specialists cooperate closely with global key opinion leaders to provides tomorrow’s innovations in today’s vitreoretinal surgery.

Vitreq will gained strong brand awarenes within the ophthalmic society. With the assistance of its new shareholder Beaver-Visitec International, Vitreq seeks to further expand its product portfolio resulting in additional innovative vitreoretinal products in the coming years.

Headquartered in Waltham, Massachusetts, Beaver-Visitec International, develops, manufactures and markets ophthalmic and other specialty microsurgical products. Beaver-Visitec distributes products in over 90 countries worldwide and operates manufacturing facilities in the US, the UK and internationally. Beaver-Visitec offers products and services for all aspects of ophthalmic surgery, including cataract, refractive, oculoplastic, and vitreoretinal sub-specialties, as well as other specialty microsurgery procedures.

Oaklins' team in the Netherlands acted as the exclusive M&A advisor to Vitreq’s shareholders in this transaction.